ScreenerHero
NTRANatera, Inc.
NAS · US · Healthcare · Diagnostics & Research · natera.com
327.30USD+0.69%Mkt Cap: 46.86B $P/E: —

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence mon…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$226.85BUSDP/E 33.1
DHR
Danaher Corporation
$151.78BUSDP/E 38.6
LONN
Lonza Group Ltd
$46.70BUSDP/E 37.9
IDXX
IDEXX Laboratories, Inc.
$44.35BUSDP/E 39.5
A
Agilent Technologies, Inc.
$44.14BUSDP/E 31.4
IQV
IQVIA Holdings Inc
$41.03BUSDP/E 31.0
WAT
Waters Corporation
$40.83BUSDP/E 105.8
ILMN
Illumina, Inc.
$30.95BUSDP/E 38.2
MTD
Mettler-Toledo International, Inc.
$28.55BUSDP/E 32.1
LH
Labcorp Holdings Inc.
$26.80BUSDP/E 27.4
DGX
Quest Diagnostics Incorporated
$26.68BUSDP/E 25.6
GH
Guardant Health, Inc.
$21.92BUSD
MEDP
Medpace Holdings, Inc.
$16.98BUSDP/E 35.8
ERF
Eurofins Scientific SE
$13.65BUSDP/E 25.3
CRL
Charles River Laboratories International, Inc.
$13.84BUSD
RVTY
Revvity Inc. Common Stock
$13.33BUSDP/E 57.4
BIM
bioMérieux S.A.
$9.55BUSDP/E 19.1
QIA
Qiagen N.V.
$8.69BUSDP/E 22.8
TWST
Twist Bioscience Corp.
$8.93BUSD
RDNT
RadNet, Inc.
$5.94BUSD

Key Statistics

Company
Market Cap46.86B $
Enterprise Value45.97B $
Revenue (TTM)2.71B $
Gross Profit1.49B $
Net Income (TTM)-208.16M $
Revenue/Share19.32 USD
Last Price327.30 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees6.1K
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3641.70
PEG—
EV/EBITDA-204.84
EV/Revenue16.98
P/S17.30
P/B26.14
EPS (TTM)-1.36
EPS (Forward)-0.09
52W Range
156.71100% of range326.03
52W High326.03 USD
52W Low156.71 USD
Profitability
Gross Margin64.75%
Oper. Margin-10.29%
EBITDA Margin-8.29%
Profit Margin-9.03%
ROE-12.16%
ROA-8.68%
Growth
Revenue Growth37.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF215.30M $
CapEx (TTM)139.19M $
FCF Margin3.84%
FCF Yield0.22%
Net Debt-853.01M $
Net Debt/EBITDA3.80
Balance Sheet
Debt/Equity0.13
Current Ratio3.00
Quick Ratio2.74
Book Value/Sh12.43 USD
Cash/Share7.572 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)336.74 USD
Upside (mean)+2.9%
Target Range280.00 USD – 375.00 USD
$280.00+2.9% to mean$375.00
# Analysts21
Ownership
Shares Out.144.14M
Float139.93M
Insiders2.85%
Institutions96.57%
Short Interest
Short Ratio3.8d
Short % Float3.12%
Short % Out.3.03%
Shares Short4.37M
Short (prev mo.)5.82M
Technical
SMA 50270.34 (+21.1%)
SMA 200228.66 (+43.1%)
Beta1.51
S&P 52W Chg18.16%
Avg Vol (30d)1.21M
Avg Vol (10d)1.68M
Technical Indicators
RSI (14)71.0
MACD16.1000
MACD Signal12.9474
MACD Hist.+3.1526
BB Upper338.54 USD
BB Middle285.35 USD
BB Lower232.16 USD
BB Width37.28%
ATR (14)12.95 USD
Vol Ratio (20d)1.26x